Chymotrypsin® (Chymotrypsin®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceChymotrypsinChymotrypsin
Similar drugsTo uncover
  • Chymotrypsin®
    lyophilizate for injections 
    SAMSON-MED, LLC     Russia
    • Dosage form: & nbsp

    Liofilizate for the preparation of solution for injection, local and external use.

    Composition:

    1 bottle contains chymotrypsin, an enzyme preparation of proteolytic action, obtained from the pancreas of cattle -10 mg.

    Description:

    Lyophilized mass in the form of a tablet, lumps, powder, plates or shiny scales of white color.

    Pharmacotherapeutic group:Proteolytic agent
    ATX: & nbsp

    B.06.A.A.04   Chymotrypsin

    Pharmacodynamics:

    Hydrolyses proteins and peptones with the formation of relatively low-molecular peptides, cleaves the bonds formed by the residues of aromatic amino acids (tyrosine, tryptophan, phenylalanine, methionine).

    In medical practice, the use of Chymotrypsin is based on a specific feature to cleave necrotic tissues and fibrinous formations, dilute viscous secrets, exudates and blood clots, and with intramuscular administration, have an anti-inflammatory effect. In relation to healthy tissues, the enzyme is inactive and safe.

    Indications:

    Suppurative diseases of the respiratory system (bronchoectatic disease, pneumonia, lung abscess, atelectasis, exudative pleurisy, empyema of the pleura, bronchitis).

    Burns, pressure sores, purulent wounds.

    Thrombophlebitis, periodontitis (inflammatory-dystrophic forms).

    In ophthalmology: fresh extensive central thrombosis, retinal veins, acute obstruction of the central artery of the retina, turbidity of the vitreous body of traumatic and inflammatory origin, extraction of cataracts.

    In otolaryngology: purulent sinusitis, subacute laryngotracheitis, after tracheostomy to facilitate the removal of dense viscous exudate, with acute, subacute, purulent, chronic otitis media and eustachytes with viscous exudate.

    Contraindications:

    Hypersensitivity, malignant neoplasms, pulmonary tuberculosis (open form), chronic heart failure of II - III degree, dystrophy and cirrhosis of the liver, viral hepatitis, pancreatitis, hemorrhagic diathesis, pulmonary emphysema.

    Do not enter into bleeding cavities, apply to ulcerated surfaces of malignant tumors to avoid the spread of malignant process.

    Carefully:

    Empyema pleura tuberculosis etiology (resorption of exudate may in some cases to promote the development of bronchopleural fistula).

    Pregnancy and lactation:

    There are no data on the use of the drug during pregnancy and during lactation.

    Dosing and Administration:

    For intramuscular injection, immediately before use, 5 mg of the drug in 1-2 ml of 0.9% solution of sodium chloride for injection or 0.5-2% of the solution of procaine. The course of treatment - 6-15 injections.

    In diseases of the respiratory system the drug is used intramuscularly in doses of 5-10 mg per day for 10-12 days, it is possible to combine with the use of Chymotrypsin aerosol in 5% aqueous solution in an amount of 3-4 ml. After 7-10 days, the course of treatment can be repeated.

    When treating burns and bedsores Chymotrypsin in a dose of 20 mg is dissolved in 20 ml of 0.25% solution of procaine and a thin needle is injected under the scab with several injections. On purulent wound surfaces, sterile wipes moistened with a solution of 25-50 mg of Chymotrypsin in 10-50 ml of 0.25 % solution of procaine. For treatment of purulent wounds, intramuscular injections of the preparation are combined with local treatment of the wound with tampons moistened with 5 % aqueous solution of Chymotrypsin.

    With thrombophlebitis, the drug is administered intramuscularly at 5-10 mg daily for 7-10 days.

    When extracting cataracts Chymotrypsin in the dilution 1: 5000 is introduced into the posterior chamber of the eye, followed by washing the anterior chamber, eyes 0.9 % solution of sodium chloride 4 minutes after the administration of the drug.

    In the treatment of thrombosis of the central vein of the retina, acute obstruction of the central artery of the retina Chymotrypsin is administered subconjunctivally in 0.2 ml of 5 % solution, prepared on a 1% solution of procaine, 1-2 times a week.

    With sinusitis, the drug is injected into the corresponding cavity in an amount of 5-10 mg in 3-5 ml of 0.9 % solution of sodium chloride after puncture and rinsing of the cavity.

    In otitis, 0.5-1 ml of a 0.1% solution of Chymotrypsin is injected into the ear in a 0.9% solution of sodium chloride. With microopuncture on the ear to soften the fibrinous formations in the middle ear during the operation, a 0.1% solution of Chymotrypsin is injected into the cavity. Simultaneously Chymotrypsin should be administered intramuscularly at 2.5-5 mg 1-2 times a day. The drug is diluted in 1-2 ml of 0.25-0.5 % a solution of procaine or a 0.9% solution of sodium chloride for injection.

    Side effects:

    Allergic reactions, fever to subfebrile, tachycardia.

    After inhalation: irritation of the mucous membranes of the upper respiratory tract, hoarseness of the voice.

    With subconjunctival administration, irritation and swelling of the conjunctiva are possible; in such cases it is recommended to reduce the concentration of the solution used.

    After intramuscular injection, pain and hyperemia may occur at the injection site.

    Overdose:There is no information about an overdose.
    Interaction:

    Not described.

    Effect on the ability to drive transp. cf. and fur:

    There were no negative effects on the ability to drive vehicles and mechanisms.

    Form release / dosage:

    Liofilizate for the preparation of solution for injection, local and external use.

    Packaging:

    For 10 mg in glass bottles with a capacity of 5 ml, corked with rubber stoppers and rolled with aluminum caps. 10 bottles per pack of cardboard with a liner and instructions for use.

    Storage conditions:

    In the dark place at a temperature of no higher than 20 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-000125
    Date of registration:18.02.2010
    The owner of the registration certificate:SAMSON-MED, LLC SAMSON-MED, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp06.09.2015
    Illustrated instructions
      Instructions
      Up